|
Loncastuximab tesirine Clinical Trials
4 actively recruiting trials across 3 locations
▼ -2 trials since July 2026
Also known as: ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402, Lonca, Loncastuximab Tesirine-lpyl +5 more
Pipeline
Phase 2: 3Phase 2/3: 1
Top Sponsors
- University of Birmingham1
- M.D. Anderson Cancer Center1
- Juan P. Alderuccio, MD1
- City of Hope Medical Center1
Indications
- Cancer4
- Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma1
- Refractory Transformed Chronic Lymphocytic Leukemia1
- Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma1
- Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma1
Other1 trial
Duarte, California1 trial
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2
Fort Myers, Florida1 trial
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Florida Cancer Specialists and Research Institute
Phase 2
Houston, Texas1 trial
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
MD Anderson Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.